Effect of an Add-On SGLT2 Inhibitor on the Efficacy of DPP-4 Inhibitor Therapy in Improving Postprandial Hyperglycemia

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2308-PUB
Author(s):  
TETSUROU ONISHI ◽  
YUKIKO TANIGUCHI ◽  
YUTAKA MORI
Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2220-PUB
Author(s):  
JUAN J. GORGOJO-MARTINEZ ◽  
MANUEL A. GARGALLO-FERNANDEZ ◽  
ALBA GALDON ◽  
TERESA ANTÓN-BRAVO ◽  
MIGUEL BRITO-SANFIEL ◽  
...  

Bone ◽  
2016 ◽  
Vol 82 ◽  
pp. 101-107 ◽  
Author(s):  
Kathryn M. Thrailkill ◽  
R. Clay Bunn ◽  
Jeffry S. Nyman ◽  
Mallikarjuna R. Rettiganti ◽  
Gael E. Cockrell ◽  
...  

Endocrine ◽  
2017 ◽  
Vol 56 (1) ◽  
pp. 212-216 ◽  
Author(s):  
A. Pfützner ◽  
D. Klonoff ◽  
L. Heinemann ◽  
N. Ejskjaer ◽  
J. Pickup

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Atsushi Tanaka ◽  
Koichi Node

AbstractSodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF). The mechanisms by which SGLT2 inhibitors reduce such risk are likely to be independent of diabetes status and improvement of glycemic control. In this commentary, based on recent mediation analyses of cardiovascular outcome trials with SGLT2 inhibitors, we discuss the prognostic role of a well-known HF-related biomarker, amino-terminal pro-B-type natriuretic peptide (NT-proBNP), in patients receiving SGLT2 inhibitors. Interestingly, the NT-proBNP concentration had a relatively small impact on the SGLT2 inhibitor-associated benefit on HF events, suggesting a limited value in measuring NT-proBNP concentrations to monitor effects on cardiovascular outcomes after initiation of SGLT2 inhibitor therapy. Instead, clinical factors, such as body weight and volume status, were prognostic for cardiovascular outcomes. As shown in some biomarker studies, short-term SGLT2 inhibitor treatment significantly improved volume and HF-related health status, despite the absence of a significant change in NT-proBNP concentration. Given the early and continuous risk reduction in HF events seen in the cardiovascular outcome trials with SGLT2 inhibitors, changes in these fundamental clinical parameters after initiation of SGLT2 inhibitor therapy, independent of NT-proBNP, could be more prognostic and could represent key determinants to identify responders or non-responders to SGLT2 inhibitors for cardiovascular outcomes. Thus, this commentary highlights the clinical importance of establishing how clinicians should monitor patients initiating SGLT2 inhibitor therapy to predict the expected cardiovascular benefit. Further detailed investigations and discussion to better understand this ‘‘black box’’ are urgently warranted.


2020 ◽  
Vol 98 ◽  
pp. 227-229
Author(s):  
Ralph Wendt ◽  
Diana Schmerler ◽  
Charlotte Müller-Hechler ◽  
Christian Weichold ◽  
Diana Craatz ◽  
...  

2021 ◽  
Author(s):  
Bingxian Xie ◽  
Wesley Ramirez ◽  
Amanda M. Mills ◽  
Brydie R. Huckestein ◽  
Moira Anderson ◽  
...  

Abstract BackgroundSodium-glucose co-transporter type 2 (SGLT2) inhibitor therapy to treat type 2 diabetes unexpectedly reduced all-cause mortality and hospitalization due to heart failure in several large-scale clinical trials, and has since been shown to produce similar cardiovascular disease-protective effects in patients without diabetes. How SGLT2 inhibitor therapy improves cardiovascular disease outcomes remains incompletely understood. Metabolic flexibility refers to the ability of a cell or organ to adjust its use of metabolic substrates, such as glucose or fatty acids, in response to physiological or pathophysiological conditions, and is a feature of a healthy heart that may be lost during diabetic cardiomyopathy and in the failing heart. While several studies have addressed metabolic changes in hearts in response to SGLT2 inhibitor therapy, none have specifically assessed metabolic flexibility in an in vivo system. We therefore undertook the described studies to determine the effects of SGLT2 inhibitor therapy on cardiac metabolic flexibility in vivo in obese, insulin resistant mice.MethodsDiet-induced obese mice were treated with the SGLT2 inhibitor empagliflozin (EMPA; 10 mg/kg/d) for four weeks prior to study and compared with untreated obese and lean controls. We assessed changes in body weight and composition, plasma metabolites in response to fasting/re-feeding, cardiac hypertrophy by echocardiography, the response to ischemic stress following coronary artery ligation, as well as cardiac-specific rates of relative glucose and fatty acid utilization using a [U13C]-glucose infusion during fasting and hyperinsulinemic euglycemic clamp.ResultsEMPA-treated mice presented with reduced cardiac hypertrophy and protection from ischemic stress compared with obese controls. In the fasted state, relative rates of cardiac glucose and fatty acid utilization were similar in control and EMPA-treated mice. During the hyperinsulinemic euglycemic clamp, rates of cardiac glucose utilization and metabolic flexibility were reduced in obese compared with lean mice, and EMPA-treatment partially restored both features. ConclusionsSGLT2 inhibitor therapy restored cardiac metabolic flexibility in obese, insulin resistant mice, and was associated with reduced cardiac hypertrophy and protection from ischemia. These observations suggest that the cardiovascular disease-protective effects of SGLT2 inhibitors may in part be explained by beneficial effects on cardiac metabolic substrate selection.


2021 ◽  
Vol 9 (11) ◽  
Author(s):  
David Bobrowski ◽  
Reha Kumar ◽  
Peter E. Wu ◽  
Lauren Lapointe‐Shaw

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 117-LB
Author(s):  
STEPHAN SIEBEL ◽  
NEHA S. PATEL ◽  
ALFONSO GALDERISI ◽  
LORI R. CARRIA ◽  
WILLIAM V. TAMBORLANE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document